A Review on Medicinal Plants Against Various forms of Dementia

Shivani Ashok Shelke*, Nachiket Jitendra Joshi
Department of Quality Assurance, Department of Pharmaceutical Chemistry, Vivekanand Education Society’s College of Pharmacy, Chembur (East), Mumbai- 4000 74, Maharashtra, India.
*Corresponding author’s E-mail: shivanishelke315@gmail.com

Received: 16-07-2020; Revised: 24-09-2020; Accepted: 02-10-2020; Published on: 20-10-2020.

ABSTRACT

Dementia includes a wide range of neurodegenerative diseases which leads to various complications of the brain functioning. It is a clinical syndrome wherein gradual decline of mental and cognitive abilities occurs and this in a way renders an individual insufficient to function on his own due to severe memory loss. Various types of dementia are Parkinson’s disease with dementia (PDD), Lewy body dementia (LBD), Vascular dementia (VaD), Huntington’s Disease with dementia (HD), Frontotemporal dementia (FTD), Creutzfeldt-jakob dementia (CJD) and Alzheimer’s disease with dementia (ADD). Medicinal plants used in dementia show varied mechanisms including effects on β-Amyloid plaque formation, Acetylcholinesterase (AChE), α and β-secretase, NMDA receptors, glutathione levels and cerebral blood flow. There have been a lot of medicinal plants used for trials against dementia and most of them have shown to have promising results in-vitro. This review article is about different medicinal plants which can potentially treat dementia.

Keywords: Parkinson’s disease with dementia, Lewy body dementia, Vascular dementia, Huntington’s disease with dementia, Frontotemporal dementia, Alzheimer’s disease with dementia, Medicinal plants.

INTRODUCTION

The International Classification of Diseases (ICD 10, WHO, 1992) defines dementia as a “syndrome due to disease of the brain, usually of a chronic or progressive nature, due to which there is obstruction of multiple higher cortical functions, including memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement”. Dementia includes a wide range of neurodegenerative diseases which results in various complications of the brain functioning. Dementia is related to various other conditions like deficits in cerebral blood flow, mitochondrial dysfunction and oxidative damage. It is a clinical syndrome wherein gradual decline of mental and cognitive abilities occurs and this in a way renders an individual insufficient to function on his own due to severe memory loss. Metabolic disorders, which participate in dysregulation of energy management, AIDS which causes indirect damage to the brain via immune-activated macrophages or systemic infections often result in dementia. Some environmental factors like toxins present in the abuse substances or air pollution can also lead to neuronal damage and thereby to dementia. Dementia is also connected with various gene polymorphisms and genetic mutations.¹ Dementia is primarily of following types:

Parkinson’s disease with dementia (PD)

Cortical tissue size reduction has been observed to be one of the main causes of PD along with presence of subcortical lesions.² This is a type of dementia which occurs at a later stage proceeding a Parkinson’s disease. This dementia is characterized by a progressive dysexecutive syndrome, forgetfulness, slowing of thought processes and impaired ability to manipulate acquired knowledge with added complications in cognition and other psychotic symptoms. Hallucinations usually of the visual type including clear, colorful and rarely fragmented figures of family and friends were observed. Treatment of dementia included synthetic drugs which improved cognition and hallucination symptoms like Donepezil, thereby only providing symptomatic relief and not treating the root cause of the disease. Rivastigmine which is a dual cholinesterase inhibitor namely butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) was also used. The extrapyramidal symptoms were found to be effectively controlled by Rivastigmine.³

Lewy body dementia (LBD)

Lewy bodies were found to be bodies of varying shapes like round, triangular and irregular. They were found to be present beside the nucleus in truncated forms.⁴ They have a dense inner core and an outer portion consisting of abnormally condensed and phosphorylated neurofilament proteins like ubiquitin, α-synuclein and associated enzymes. Visual hallucinations, olfactory and auditory disturbances were commonly observed in patients with LBD. These hallucinations resulted in varying emotional states like fear, amusement, anger etc. Hypophonic speech, stooped posture and gait were also found to be
prevalent in patients.\textsuperscript{5} Treatment therapy consisted of synthetic agents namely antipsychotics likeClozapine, Chlormethiazole and lorazepam. Neuroleptics like Thioridazine and Sulpiride were also used.\textsuperscript{6}

**Vascular dementia (VaD)**

It is one of the most common types of dementia which involves cognitive impairment which precipitates because of an existing vascular disorder like a cardiac stroke, atherosclerosis or cardiac arrest which leads to multiple cerebral tissue lesions like Hemorrhage infarction, Hippocampal sclerosis and white matter lesions. These changes then in a way lead to dementia.\textsuperscript{7} The symptoms associated with this disease are motor delay, depressive mood, low motivational energy, anxiety, abnormal thoughts and somatic irregularities. Cerebrovascular injury can also lead to corticospinal and extrapyramidal side effects like weakness and slowed muscular movements that in a way contribute to delaying of the behavioural patterns and decision-making abilities.\textsuperscript{8} Treatment was done using Donepezil which improved cognition in patients, but it was shown to have a variety of side-effects. Rivastigmine showed considerable progress in executive functioning, verbal fluency as well as the behavioural patterns. Memantine showed a mild effect on improving cognition but had less side-effects in patients.\textsuperscript{9}

**Huntington’s disease with dementia (HD)**

Huntington’s disease is a type of genetic disease with abnormalities in the Huntington gene which can then precipitate into dementia. Symptoms associated with the disease is a combination of three types of impairments namely:

1. **Movement disorders:** These consist of voluntary and involuntary disorders. These consist of continuous and irregular jerky movements. Unnatural eye movements, dysphagia, muscular rigidity and posture disturbances.

2. **Cognitive disorders:** Aphasia, agnosia, shortcomings in cognitive speed and flexibility are common. Retrieving memories and past events is a major problem observed in patients. Also, visuospatial activity and judgemental defects were known to develop.

3. **Psychotic disorders:** Depression, irritation and apathy are the most commonly observed. Prominent symptoms include feelings of worthlessness, self-blame, changes in sleep patterns, changes in appetite, anxiety, loss of energy and hopelessness.\textsuperscript{10}

Treatment included synthetic drugs like Amantadine, Levetiracetam and Tetrabenazine. Also, some neuroprotective in clinical trials included Coenzyme-Q10, Creatine and Minocycline.\textsuperscript{11} Several selective serotonin reuptake inhibitors were also used and were believed to benefit HD patients. Mood stabilizers like carbamazepine and valproate were thought to help with emotional stability and impulsivity. Antipsychotics were thought to benefit psychosis-related symptoms. Donepezil, Rivastigmine and Memantine were found to show questionable benefits in clinical trials.\textsuperscript{12}

**Frontotemporal Dementia (FTD)**

It is a differential type of dementia with its locus in the frontal and/or temporal lobes involving progressive atrophy. It is also called Pick’s disease after a Physician Arnold Pick. The three major pathogenic proteins implicated for the development of FTD are phosphorylated tau protein, trans active response DNA-binding protein-43 (TDP-43) and fused in sarcoma (FUS) protein.\textsuperscript{13}

Two vivid types of FTD exist:

1. **Behavioral variant FTD:** It includes personality changes, disinhibition and apathy. Reduced inhibition often results in poor financial decision making that can lead to financial ruins. Patients show loss of sympathy and empathy towards family and friends. A decrease in social responsiveness to emotional and other needs of people. Binge-eating, increased consumption of sweets or alcohol and weight gain are different aspects of this type.

2. **Progressive Aphasia:** Defects in language prediction, object naming, syntax or word comprehension are apparent during conversation.

Motor symptoms include hyperreflexia, spasticity, weakness, muscle atrophy and dysphagia are observed.\textsuperscript{14} A lot of synthetic drugs were used. Commonly, selective serotonin reuptake inhibitors like Fluoxetine, Fluvoxamine, Sertraline or Paroxetine showed improvement in neuropsychiatric disorders. Antipsychotics like Olanzapine, Risperidone and Aripiprazole showed improvements in cognitive abilities, delusions, agitation, neuropsychiatric symptoms and overall behaviour. Cholinergic drugs like Rivastigmine, Donepezil and Selegiline showed improved behaviour and cognition.\textsuperscript{15} But these synthetic drugs could only alleviate the symptoms rather than treating the root cause.

**Creutzfeldt-Jakob dementia (CJD)**

It is one of the rarest forms of dementia which can be a familial, sporadic or iatrogenic type. The basic event which happens is the formation of abnormal prion protein. It is hypothesized to occur in a pathway where abnormal prion protein acts as a template for host prion protein to fold abnormally into a pathogenic conformation which causes this type of dementia. This process is autocatalytic.\textsuperscript{16} The synthetic drugs which were tried in trials included Quinacrine which reduced cyclic amplification of prion proteins and their cyclization yet did not show efficacy.\textsuperscript{17} Flupirtine was found to act as a neuroprotective by upregulation of proto-oncogene bcl-2 and normalization of glutathione levels. There was a significant improvement in cognition among CJD patients.\textsuperscript{18} Pentosan polysulfate was observed to have completely removed the abnormal prion protein strain in the mice population, but was yet to be tested for efficacy in humans.\textsuperscript{19} These synthetic drugs would not show efficacy.
however could only provide symptomatic relief and there remains no cure for this form of dementia.\textsuperscript{17}

**Alzheimer’s disease (AD)**

AD is characterized by loss of presynaptic cholinergic neurons which later proceeds to cortical cholinergic deficit and thus into dementia.\textsuperscript{20} The hallmark of this type of dementia is deposition of amyloid β-protein (Aβ complex) in the extracellular cortical plaques and formation of neurofibrillary tangles composed of phosphorylated tau-protein. These events in the hippocampus, cortex and nucleus basalis lead to cholinergic, serotonergic and noradrenergic deficits.\textsuperscript{21} Symptoms of this type include disorientation, agitation, confusion, hallucinations, apathy, depression and urinary incontinence. Rigidity, tremor, tardive dyskinesia, snout and grasp reflex, Babinski reflexes were the extrapyramidal symptoms observed.\textsuperscript{22} Many synthetic drugs were used to treat AD. Cholinesterase inhibitors like tacrine, donepezil and rivastigmine were primarily used. Xanomeline and Milameline were the muscarinic cholinergic agonists which were also tested for their efficacy on providing symptomatic relief. Most of these drugs were only able to treat the cognitive deficits which was observed during the testing studies.\textsuperscript{20}

FDA approved drugs for most forms of dementia include Rivastigmine, Donepezil, Memantine and Galantamine.\textsuperscript{1} Other synthetic drugs only provide symptomatic relief to demented patients, hence there is a dire need to look for more drugs which could potentially treat dementia. Medicinal plants can help in this regard. Medicinal plants have a wide range of phytoconstituents which show wide varieties of activity. Such plants offer a manifold benefit against the progression as well as against the symptoms associated with various forms of dementia. Medicinal plants used in dementia show different mechanisms including effects on modulation of β-Amyloid plaque formation, acetylcholinesterase, α and β-secretase, NMDA receptors, glutathione levels and cerebral blood flow. There have been a wide range of medicinal plants used for trials against dementia and most of them have shown to have promising biological activities.

Flowchart depicting various types of dementia and medicinal plants which can potentially treat dementia are mentioned in Figure 1.

![Figure 1: Flowchart representing types of dementia and the medicinal plants tried for treatment](image)

These medicinal plants as well as their phytoconstituents responsible for activity have been listed in table 1.
### Table 1: Medicinal plants, their active constituents, part of plant used and mechanism of action

| Common name and Family | Botanical name and Family | Chemical constituents | Form/ fraction of the plant | Used against type of dementia | Mechanism of action |
|------------------------|---------------------------|-----------------------|-----------------------------|-------------------------------|---------------------|
| Maidenhair tree, Kew tree | *Ginkgo biloba* | Quercetin, kaempferol, ginkgolides | Leaves | VaD, AD | Enhances memory by increasing the availability of oxygen and help to eliminate free radicals from the system |
| Turmeric | *Curcuma longa* | Curcumin, curcuminoids | Roots and rhizomes | AD, HD, PD, VaD | Decrease in the formation of amyloid plaques and delay in degradation of neurons. |
| Toothed clubmoss | *Huperzia serrata* | Huperzine A, huperzine B | Moss | VaD, AD | Inhibition of AChE, anti-β-amyloid peptide fragmentation, inhibition of oxygen-glucose deprivation, and NMDA receptor antagonism |
| Asian ginseng, Chinese ginseng | *Panax ginseng* | Ginsenoside Rg5, ginsenoside Rg3 | Whole plant | VaD | Promotes β-amyloid peptide degradation and inhibition of AChE |
| Saffron | *Crocus sativus* | Crocin, safranal, crocin | Flower | AD | Inhibition of oxidation induced formation of toxic amyloid fibrils |
| Gall nut | *Terminalia chebula* | Chebulic acid, gallic acid, ellagic acid | Fruit | AD | Inhibition of AChE and BuChE levels |
| Ashwagandha | *Withania somnifera* | Withanolide A, withanolide IV, withanolide VI, sitoindosides VII - X | Roots | PD, AD, HD | Inhibition of AChE and decrease in level of β-amyloid peptide and glutathione level |
| Water hyssop, Brahmi | *Bacopa monnieri* | Bacoside A, bacoside B | Rhizome | AD, VaD | Decrease in AChE, prevents β-amyloid deposits and formation of fibril |
| Tea plant, Tea shrub | *Camellia sinensis* | Epigallocatechin-3-gallate | Leaves | VaD | Elevation of α-secretase activity and inhibition of β-secretase activity |
| Gotu kola | *Centella asiatica* | Asiaticoside, centelloside, brahmoside | Flowers | AD, HD | Inhibition of AChE inhibitor activity, decrease in level of β-amyloid and oxidative stress |
| Sage | *Salvia officinalis* | Urosolic acid, Rosmarinic acid | Leaves | AD | Reduction in AChE and BuChE levels |
| Velvet bean | *Mucuna pruriens* | Gallic acid, glutathione, levodopa | Seeds | PD | Reduction in oxidative stress, mitochondrial and synaptic function |
| Huang lian | *Rhizoma Coptidis* | Berberine, palmatine, coptisine, protopine, epiberberine, jatrorrhizine, | Rhizomes | AD, VaD | Reduction in β-amyloid aggregation, oxidative stress and inhibition of cholinesterase activity |
| Lavender | *Lavandula angustifolia* | Linalool, linalyl acetate, lavandulol, geraniol | Flowers | AD | Inhibition of β-amyloid plaque formation |
| Plant Name | Family | Parts Used | AD/ PD | Action |
|------------|--------|------------|--------|--------|
| Houpa magnolia | Magnolol, honokiol | root and stem bark | AD | Inhibition of AChE activity and prevention of β-amyloid accumulation |
| Shankhpushpi | Scopoline, β-Sitosterol, convolvidine, subhirsine, convolvine, phyllabine, convolone, confoline | Whole plant | AD, PD | Inhibition of AChE level and β-amyloid plaque formation |
| Dong quai, female ginseng | Z-liguistilide, 11-angeloylsenkyunolide F, coniferyl ferulate, ferulic acid | Roots | AD | Lowers hippocampal levels of Aβ and β-site amyloid precursor protein-cleaving enzyme |
| Feru-guard | Ferulic acid | Whole plant | LBD, FTD | Inhibition of AChE activity and increase acetylcholine in the synapse |
| Salparni | Gangetin, gangetinin, desmocarpine, desmodin | Whole plant | AD | Decrease in AChE level |
| Three-leaf corydalis | Protopine, coptisine, berberine | Tuber | AD | Inhibition of AChE activity |
| Agati, hummingbird tree | Oleanolic acid, glucuronic acid | Leaves and Flowers | AD | Decrease in AChE level |
| Star anise | Anethole | Fruits | AD | Inhibition of AChE and BuChE |
| Five-flavor berry | Schizandrin | Fruits | PD | Reduction of oxidative stress, dopamine and tyrosine hydroxylase levels |
| Flannel weed, country mallow | B-phenethylamine, tryptamines, vasicine, vasicinol | Roots | PD | Reduction of dopamine and oxidative stress levels |
| Yi-gan san | 18 β-glycyrrhetic acid, geissoschizine methyl ether, hirsutene. | Roots, fungus, hooks | FTD | Decrease in brain glutamate level and modulation of serotonin function |
| Snowdrop | Galantamine | Bulb | AD | Inhibition of AChE and enhancement of cholinergic function, reduction in oxidative stress |

The chemical structures for the above-mentioned chemical constituents as per the order stated as above are given in Table 2.
### Table 2: Chemical constituents and their structure

| Chemical constituent | Structure | Chemical constituent | Structure |
|----------------------|-----------|----------------------|-----------|
| Quercetin            | ![Quercetin](image1.png) | Kaempferol           | ![Kaempferol](image2.png) |
| Ginkgolides          | ![Ginkgolides](image3.png) |
| Ginkgolide A         | R1= H  R2= OH  R3= H |
| Ginkgolide B         | R1= H  R2= OH  R3= OH |
| Ginkgolide C         | R1= OH  R2= OH  R3= OH |
| Ginkgolide J         | R1= OH  R2= OH  R3= H |
| Ginkgolide M         | R1= OH  R2= H  R3= OH |
| Bilobalide           | ![Bilobalide](image4.png) |
| Curcumin             | ![Curcumin](image5.png) | Demethoxycurcumin   | ![Demethoxycurcumin](image6.png) |
| Bisdemethoxycurcumin | ![Bisdemethoxycurcumin](image7.png) | Huperzine A         | ![Huperzine A](image8.png) |
| Huperzine B          | ![Huperzine B](image9.png) | Ginsenoside Rg5     | ![Ginsenoside Rg5](image10.png) |
| Ginsenoside Rg3      | ![Ginsenoside Rg3](image11.png) | Crocin              | ![Crocin](image12.png) |
| Crocetin             | ![Crocetin](image13.png) | Safranal            | ![Safranal](image14.png) |
| Chebulic acid        | ![Chebulic acid](image15.png) | Ellagic acid        | ![Ellagic acid](image16.png) |
| Compound                | Chemical Structure                                                                 |
|------------------------|-----------------------------------------------------------------------------------|
| Gallic acid            | ![Gallic acid](image)                                                              |
| Withanolide A          | ![Withanolide A](image)                                                           |
| Withanoside IV         | ![Withanoside IV](image)                                                          |
| Withanoside VI         | ![Withanoside VI](image)                                                          |
| Sitoindoside VII       | ![Sitoindoside VII](image)                                                         |
| Sitoindoside VIII      | ![Sitoindoside VIII](image)                                                        |
| Sitoindoside IX        | ![Sitoindoside IX](image)                                                          |
| Bacoside A             | ![Bacoside A](image)                                                              |
| Bacoside B             | ![Bacoside B](image)                                                              |
| Brahmoside             | ![Brahmoside](image)                                                              |
| Asiaticoside           | ![Asiaticoside](image)                                                             |
| Centelloside           | ![Centelloside](image)                                                             |
| Ursolic acid           | ![Ursolic acid](image)                                                             |
| Rosmarinic acid        | ![Rosmarinic acid](image)                                                          |
| Gallic acid            | ![Gallic acid](image)                                                              |
| Glutathione            | ![Glutathione](image)                                                              |
| Levodopa               | ![Levodopa](image)                                                                |
| Berberine              | ![Berberine](image)                                                               |

**Chemical Structures:**

1. **Gallic acid**
2. **Withanolide A**
3. **Withanoside IV**
4. **Withanoside VI**
5. **Sitoindoside VII**
6. **Sitoindoside VIII**
7. **Sitoindoside IX**
8. **Bacoside A**
9. **Bacoside B**
10. **Brahmoside**
11. **Asiaticoside**
12. **Centelloside**
13. **Ursolic acid**
14. **Rosmarinic acid**
15. **Gallic acid**
16. **Glutathione**
17. **Levodopa**
18. **Berberine**
| Compound          | Structure 1          | Structure 2          | Structure 3          |
|-------------------|----------------------|----------------------|----------------------|
| Palmatine         | ![Palmatine Structure](image1) | ![Coptisine Structure](image2) | ![Coptisine Structure](image3) |
| Epiberberine      | ![Epiberberine Structure](image4) | ![Jatrorrhizine Structure](image5) | ![Jatrorrhizine Structure](image6) |
| Protopine         | ![Protopine Structure](image7) | ![Linalool Structure](image8) | ![Linalool Structure](image9) |
| Linalyl acetate   | ![Linalyl Acetate Structure](image10) | ![Lavandulol Structure](image11) | ![Lavandulol Structure](image12) |
| Geraniol          | ![Geraniol Structure](image13) | ![Magnolol Structure](image14) | ![Magnolol Structure](image15) |
| Honokiol          | ![Honokiol Structure](image16) | ![Scopoline Structure](image17) | ![Scopoline Structure](image18) |
| β-sitosterol      | ![β-sitosterol Structure](image19) | ![Convolvidine Structure](image20) | ![Convolvidine Structure](image21) |
| Subhirsine        | ![Subhirsine Structure](image22) | ![Convolvine Structure](image23) | ![Convolvine Structure](image24) |
| Phyllalbine       | ![Phyllalbine Structure](image25) | ![Convoline Structure](image26) | ![Convoline Structure](image27) |
| Compound                  | Structure | Compound                  | Structure |
|--------------------------|-----------|--------------------------|-----------|
| Confoline                | ![Confoline](image) | Z-ligustilide            | ![Z-ligustilide](image) |
| 11-angeloylsenkyunolide F | ![11-angeloylsenkyunolide F](image) | Coniferyl ferulate       | ![Coniferyl ferulate](image) |
| Ferulic acid             | ![Ferulic acid](image) | Gangetin                 | ![Gangetin](image) |
| Gangetinin               | ![Gangetinin](image) | Desmocarpin             | ![Desmocarpin](image) |
| Desmodin                 | ![Desmodin](image) | Oleanolic acid           | ![Oleanolic acid](image) |
| glucuronic acid          | ![glucuronic acid](image) | anethole                | ![anethole](image) |
| Schizandrin              | ![Schizandrin](image) | Œ-phenethylamine         | ![Œ-phenethylamine](image) |
| Tryptamine               | ![Tryptamine](image) | Vasicine                | ![Vasicine](image) |
| Vasicinol                | ![Vasicinol](image) | 18 Œ-glycyrrhetinic acid | ![18 Œ-glycyrrhetinic acid](image) |
| Geissoschizine methyl ether | ![Geissoschizine methyl ether](image) | Hirsutene             | ![Hirsutene](image) |
| Galantamine              | ![Galantamine](image) |                          |           |
CONCLUSION
In recent years, herbal drugs have shown tremendous potential in treating dementia. Studies have been done on animals to prove their efficacy against dementia. Some of them have shown promising results in animal studies. From this review, it is clear that medicinal plants play a vital role against various types of dementia. These medicinal plants have phytoconstituents which improve cognitive function and act as neuroprotective. We therefore conclude that these plants have a great potential in the treatment of dementia and can be used as a monotherapy or even as adjunct therapy in combination with other drugs.

REFERENCES
1. Tewari D, Stankiewicz AM, Mocan A, Sah AN, Tzeitkov NT, Huminecki L, Horbanczuk JO and Atanassov AG, Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs, Frontiers in Aging Neuroscience, 10, 2018.
2. Martilla RJ and Rinne UK, Dementia in Parkinson’s Disease, Acta Neurologica Scandinavica, 54, 1976, 431-441.
3. Bosboom JLW, Stoffers D and Wolters EC, Cognitive Dysfunction and Dementia in Parkinson’s Disease, Journal of Neural Transmission, 111, 2004, 1303-1315.
4. Gibb WRG, Esiri MM and Lees AJ, Clinical and Pathological Features of Diffuse Cortical Lewy Body Disease (Lewy Body Dementia), Brain- A Journal of Neurology, 110, 1987, 1131-1153.
5. Mckee IHG, Galasko D, Wilcock GK and Byrne EJ, Lewy Body Dementia - Diagnosis and Treatment, The British Journal of Psychiatry, 167, 1995, 709-717.
6. Mckee IGH and Burn D, Spectrum of Parkinson’s Disease, Parkinson’s Disease and Lewy Body Dementia, Neurologic Clinics, 18, 2000, 865-883.
7. Korczyn AD, Vakapova V and Grinberg LT, Vascular Dementia, Journal of The Neurological Sciences, 322, 2012, 2-10.
8. Sultzer DL, Levin HS, Mahler E, High WM, Cummings JL and Hamilton A, Comparison of psychiatric symptoms of Lewy body dementia and Alzheimer’s disease, The American Journal of Psychiatry, 150, 1993, 1806-1812.
9. Demaerschalk BM and Wingerchuk DM, Treatment of Vascular Dementia and Vascular Cognitive Impairment, The Neurologist, 13, 2007, 37-41.
10. Ross CA and Margolis RL, Huntington Disease, Neuropsychopharmacology – 5th Generation of Progress, 5th ed, the American College of Neuropsychopharmacology, 2002, 1817-1830.
11. Walker FO, Huntington’s Disease. The Lancet, 369, 2007, 218-228.
12. Dayalu P and Albin RL, Huntington Disease: Pathogenesis and Treatment. Neurologic Clinics, 33, 2015, 101–114.
13. Warren JD, Rohrer JD and Rossor MN, Frontotemporal Dementia, The British Medical Journal, 347, 2013, 1–9.
14. Bang J, Spina S and Miller BL, Frontotemporal Dementia, The Lancet, 386, 2015, 1672–1682.
15. Boxer AL and Boeve BF, Frontotemporal Dementia Treatment: Current Symptomatic Therapies and Implications of Recent Genetic, Biochemical, and Neuroimaging Studies, Alzheimer Disease and Associated Disorders, 21, 2007, 79–87.
16. Manix M, Kalakoti P, Henry M, Thakur J, Menger R, Guthikonda B and Nanda A, Creutzfeldt-Jakob Disease: Updated Diagnostic Criteria, Treatment Algorithm, and the Utility of Brain Biopsy, Journal of Neurosurgery, 39, 2015, 1–11.
17. Barret A, Tagliavini F, Forloni G, Bate C, Salmona M, Colombo L, De Luigi A, Limido L, Suardi S Rossi G, Auvre’ F, Adjou KT, Sale’s N, Williams A, Lasme’zas C and Deslys JP, Evaluation of Quinacrine Treatment for Prion Diseases, Journal of Virology, 77, 2003, 8462–8469.
18. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, Irle E, Pergande G, Ellers-Lenz B, Windl O, Kretschmar HA, Poser S and Prange H, Efficacy of Flupirtine on Cognitive Function in Patients with CJD: A Double-Blind Study, Neurology, 62, 2004, 714–718.
19. Farquhar C, Dickinson A and Bruce M, Prophylactic Potential of Pentosan Polysulphate in Transmissible Spongiform Encephalopathies, The Lancet, 353, 1999, 117.
20. Cummings JL and Benson DF, Subcortical Dementia Emerging Concept, JAMA Neurology, 41, 1984, 874-879.
21. Farlow MR and Evans RM, Pharmacologic treatment of cognition in Alzheimer’s dementia, Neurology, 51, 1998, 36-44.
22. Sulkava R and Amberla K, Alzheimer’s Disease and Senile Dementia of Alzheimer Type: A Neuropsychological Study, Acta Neurologica Scandinavica, 65, 1982, 651–660.
23. Kleijnen J and Knipschild P, Ginkgo biloba for cerebral insufficiency, British Journal of Pharmacology, 34, 1992, 352–358.
24. Chang D, Liu J, Bilinski K, Xu L, Steiner GZ, Seto SW and Bensoussan A, Herbal Medicine for the Treatment of Vascular Dementia: An Overview of Scientific Evidence, Evidence-Based Complementary and Alternative Medicine, 2016.
25. Avneet G, Manish Pal S and Siddhraj SS, A review on herbal Ayurvedic medicinal plants and its association with memory functions, The Journal of Phytopharmacology, 7, 2018, 162–166.
26. Nishteswar K, Karra R and Joshi H, Role of indigenous herbs in the management of Alzheimer’s disease, Ancient Science of Life, 34, 2014, 3-7.
27. Sanka N, Santhigiriya N and Nandendla RR, Journal of Drug Delivery and Therapeutics, An updated review on Anti-Alzheimer’ s herbal drugs, 8, 2018, 360–372.
28. Ringman J, Frautschy S, Cole G, Masterman D and Cummings J, A Potential Role of the Curry Spice Curcumin in Alzheimer’s Disease, Current Alzheimer Research, 2, 2005, 131–136.
29. Ho YS, So KF and Chang RC, Drug discovery from Chinese medicine against neurodegeneration in Alzheimer’s and vascular dementia, Chinese Medicine, 6, 2011 2–7.
30. Kumar GP, Anilakumar KR and Naveen S, Phytochemicals having neuroprotective properties from dietary sources and medicinal herbs, Pharmacognosy Journal, 7, 2015, 1–17.
31. Kaur J, Singh R, Singh G, Kaur H, Kaur J, Kaur M, Singh P and Kaur J, A systematic review on Huperzia serrata, International Journal of Pharmacognosy and Phytochemical Research, 8, 2016, 1250–1255.
32. Xing SH, Zhu CX, Zhang R and An L, Huperzine A in the treatment of Alzheimer’s disease and vascular dementia: A meta-analysis. Evidence-Based Complementary and Alternative Medicine, 2014.
33. Zhu JD, Wang JJ, Zhang XH, Yu Y and Kang ZS, Panax ginseng extract attenuates neuronal injury and cognitive deficits in rats with vascular dementia induced by chronic cerebral hypoperfusion, Neural Regeneration Research, 13, 2018, 664–672.
34. Kyriakoudi A, Ordoudi SA, Medina MR and Tsimidou MZ, Saffron, A Functional Spice, Austin Journal of Nutrition and Food Sciences, 3, 2015, 1-5.
35. Dua JS, Prasad DN, Tripathi AC and Gupta R, Role of traditional medicine in neuropyschoparmacology, Asian Journal of Pharmaceutical and Clinical Research, 2, 2009, 72–76.
36. Afshari AR, Sadeghnia HR and Moalahadheh H, A Review on Potential Mechanisms of Terminalia chebula in Alzheimer’s Disease, Advances in Pharmacological Sciences, 2016.
37. Farooqui AA, Farooqui T, Madan A, Ong JHU and Ong WY, Ayurvedic Medicine for the Treatment of Dementia: Mechanistic Aspects, Evidence-Based Complementary and Alternative Medicine, 2018.
38. Choudhary S, Kumar P and Malik J, Plants and phytochemicals for Huntington’s disease, Pharmacognosy Reviews, 7, 2013, 81–91.
39. Dwivedi C, Chandrakar K, Singh V, Tiwari SP, Satapathy T, Kesharwani S, Kumar B and Amit Roy, Indian herbal medicines used for treatment of Dementia: An Overview, 1, 2014, 553-571.
40. Manap ASA, Vijayabalan S, Madhavan P, Chia YY, Arya A, Wong EH, Rizwan F, Bindal U and Koshy S, Bacopa monnieri, a Neuroprotective Lead in Alzheimer Disease: A Review on Its Properties, Mechanisms of Action, and Preclinical and Clinical Studies, Drug Target Insights, 13, 2019, 1-13.
41. Aguiar S and Borowski T, Neuropharmacological review of the nootropic herb Bacopa monnieri, Rejuvenation Research, 16, 2013, 313–326.
42. Tang CT, Belani LK, Das S and Jaafar MZ, Treatment of dementia with herbs: A short review, La Clinica Terapeutica, 164, 2013, 43–46.
43. Dhanasekaran M, Holcombe LA, Hitt AR, Tharakan B, Porter JW, Young KA and Manyam BV, Centella asiatica Extract Selectively Decreases Amyloid β Levels in Hippocampus of Alzheimer’s Disease Animal Model, Phytotherapy Research, 23, 2009, 14-19
44. Lopresti AL, Solvía (Sage): A Review of its Potential Cognitive-Enhancing and Protective Effects, Drugs in R and D, 17, 2017, 53–64.
45. Choudhary S, Kumar P and Malik J, Plants and phytochemicals for Huntington’s disease, Pharmacognosy Reviews, 7, 2013, 81–91.
46. Srivastava S, Fatima M and Mondal AC, Important medicinal herbs in Parkinson’s disease pharmacotherapy, Biomedicine and Pharmacotherapy, 92, 2017, 856–863.
47. Wang Z, Yang Y, Liu M, Wei Y, Liu J, Pei H and Li H, Rhizoma Coptidis for Alzheimer’s Disease and Vascular Dementia: A Literature Review, Current Vascular Pharmacology, 18, 2019, 358–368.
48. Saki K, Phytotherapies for Dementia, Journal of Biochemical Technology, 9, 2018, 108–113.
49. Kashani MS, Tavirani MR, Talaei SA and Salami M, Aqueous extract of lavender (Lavandula angustifolia) improves the spatial performance of a rat model of Alzheimer’s disease, Neuroscience Bulletin, 27, 2011, 99–106.
50. Masoud S, Khalaji F, Mirhashemi M and Salami M, The effect of essential oil of Lavandula Angustifolia on amyloid beta polymerization: An in vitro study, Iranian Journal of Chemistry and Chemical Engineering, 37, 2018, 201–207.
51. Natarajan S, Shanmugiah KP and Kasi PD, Plants traditionally used in age-related brain disorders (dementia): An ethnopharmacological survey, Pharmaceutical Biology, 51(4), 2013, 492–523.
52. Lee YJ, Choi DY, Han SB, Kim YH, Kim KH, Hwang BY, Kang JK, Lee BJ, Oh KW and Hong JT, Inhibitory effect of ethanol extract of Magnolia officinalis on memory impairment and amyloidogenesis in a transgenic mouse model of Alzheimer’s disease via regulating β-secretase activity, Phytotherapy Research, 26, 2012, 1884–1892.
53. Bihagi S, Rashaan S and Tiwari M, Convulvulus pluricaulis as a Cognition Booster: Relevance to Alzheimer’s Disease, International Journal of Pharmaceutical Sciences and Drug Research, 8, 2016, 68–74.
54. Bhowmik D, Kumar KPS, Paswan S, Srivastava S, Yadav AP and Dutta A, Traditional Indian Herbs Convulvulus Pluricaulis and Its Medicinal Importance, Journal of Pharmacognosy and Phytochemistry, 1, 2012, 37-45.
55. Duan MH, Wang LN, Jiang YH, Pei YY, Guan DD and Qiu ZD, Angelica sinensis reduced Aβ-induced memory impairment in rats, Journal of Drug Targeting, 24, 2016, 340-347.
56. Singh AK, Gupta A, Mishra AK, Gupta V, Bansal P and Kumar S, Medicinal Plant for Curing Alzheimer’s Disease, International Journal of Pharmaceutical Sciences & Biological Archives 2010, 1, 2016, 108 – 114
57. Kimura T, Hayashida H, Murata M and Takamatsu J, Effects of ferulic acid and Angelica archangelica extract on behavioral and psychological symptoms of dementia in frontotemporal lobar degeneration and dementia with Lewy bodies, Geriatrics and Gerontology International, 11, 2011, 309–314.
58. Obulesu M and Rao DM, Effect of plant extracts on Alzheimer’s disease: An insight into therapeutic avenues, Journal of Neurosciences in Rural practice, 2, 2011, 56-61.
59. Kim YJ, Lim HS, Kim Y, Lee J, Kim BY and Jeong SJ, Neuroprotective effect of Corydalis ternata extract and its phytochemical quantitative analysis, Chemical and Pharmaceutical Bulletin, 65, 2017, 826–832.
60. Joshi H, Soumya SV and Chauhan JB, Pharmacological evidence for the anti-alzheimer potentials of *Sesbania grandiflora* Linn. in mice, Natural Products, 3, 2007, 171-177.

61. Li CL, Tsuang YH and Tsai TH, Neuroprotective Effect of *Schisandra Chinensis* on Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonian Syndrome in C57BL/6 Mice, Nutrients, 11, 2019, 1-17.

62. Galal A, Raman V and Khan AI, *Sida cordifolia*, a Traditional Herb in Modern Perspective – A Review, Current Traditional Medicine, 1, 2014, 5-17.

63. Kimura T, Hayashida H, Furukawa H and Takamatsu J, Pilot study of pharmacological treatment for frontotemporal dementia: Effect of *Yokukansan* on behavioral symptoms, Psychiatry and Clinical Neurosciences, 64, 2010, 207-210.

64. Kitagawa H, Munekage M, Ichikawa K, Fukudome I, Munekage E, Takezaki Y, Matsumoto T, Igarashi Y, Hanyu H and Hanazaki K, Pharmacokinetics of Active Components of *Yokukansan*, a Traditional Japanese Herbal Medicine after a Single Oral Administration to Healthy Japanese Volunteers: A Cross-Over, Randomized Study, PloS One, 10, 2015, 1-14.

65. Dembitsky VM, Dzhemilev L, Gloriozova T and D’yakonov V, Natural and synthetic drugs used for the treatment of dementia, Biochemical and Biophysical Research Communications, 524, 2020, 1-12.

66. Mantle D, Pickering AT and Perry EK, Medicinal Plant Extracts for the Treatment of Dementia, CNS Drugs, 13, 2000, 201–213.

67. Houghton PJ and Howes MJ, Natural products and derivatives affecting neurotransmission relevant to Alzheimer’s and Parkinson’s disease, Neuro Signals, 14, 2005, 6-22.

---

**Source of Support:** None declared.

**Conflict of Interest:** None declared.

---

For any question relates to this article, please reach us at: editor@globalresearchonline.net

New manuscripts for publication can be submitted at: submit@globalresearchonline.net and submit_ijpsrr@rediffmail.com